Mykoseptin

Quick links to important sections

Mykoseptin

Selected form

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mykoseptin

Quick Facts

Property Description
Active Ingredients Undecylenic Acid, Zinc Undecylenate
Form Ointment, Cream, Topical Solution, Powder
Pharmacological Class Antifungal Agent, Topical Anti-infective
Common Purpose Inhibiting fungus growth and reducing surface irritation
Origin Derived (Bio-based organic unsaturated fatty acid component)

Mykoseptin is a well-established combination product classified as a topical anti-infective that belongs to the antifungal agent pharmacological class, utilizing the dual action of Undecylenic Acid and Zinc Undecylenate. This medication is formulated for topical administration, meaning it is applied directly to the skin, and is delivered in various pharmaceutical preparations such as ointment, cream, and topical solution.

Composition and Identity: What Type of Medicine is Mykoseptin?

Mykoseptin is a combination product that contains both the primary active agent, Undecylenic Acid, and its salt derivative, Zinc Undecylenate. The Undecylenic Acid component is a medium-chain fatty acid that is often bio-based and derived from natural sources, such as castor oil, classifying it as an organic unsaturated fatty acid. This unique pairing with its zinc salt is clinically recognized for providing a complementary effect not found in single-ingredient antifungal preparations. The formulation leverages the acid's core fungistatic properties alongside the beneficial astringent action provided by the zinc salt derivative. Undecylenic Acid is considered an agent effective against superficial fungal infections, confirming its established role in dermatological care.

General Purpose: What Does Mykoseptin Generally Help to Do?

The general purpose of Mykoseptin is to address cutaneous conditions by exerting a fungistatic effect and reducing associated skin irritation. The Undecylenic Acid component works to inhibit the growth and proliferation of dermatophytic fungi, including various Tinea species, preventing the further spread of the infection on the skin's surface. A typical application scenario involves managing irritation and controlling the fungus growth associated with Athlete's foot, without treating the root cause. This mechanism is complemented by the astringent action of the Zinc Undecylenate, which helps soothe the skin, reduce rawness, and establish a less favorable environment for continued fungus growth. The combination has the ability to maintain a dry, non-inflamed environment, which is crucial for managing these types of surface infections.

What side effects are possible with Mykoseptin?

Possible Side Effects and Safety Information

The regulatory safety profile for products containing Undecylenic Acid and Zinc Undecylenate is focused on local intolerance and constraints on use, consistent with its classification as a topical anti-infective agent. The official labeling typically lists adverse reactions as events that may occur, without formal frequency classifications (e.g., Common, Uncommon), which is standard for Over-the-Counter topical monographs.

Dermatological and Immune System Reactions

The most commonly documented adverse reactions are categorized under Skin and Subcutaneous Tissue Disorders. These reactions include local effects such as skin irritation not present before use, burning, crusting, and peeling of the skin at the application site. While rare, signs of a serious allergic reaction, which may involve rash, hives, or swelling of the face, tongue, or throat, are considered a significant safety event documented in post-market information.


Special Population and Regulatory Constraints

Official regulatory documents contain specific limitations and constraints:

  • Pediatric Use: The product is contraindicated for use in children under 2 years of age, unless explicitly directed by a physician.
  • Use Limitations: The medicine is strictly for external use only, must avoid contact with the eyes, and must not be used for the treatment of diaper rash or on badly broken skin.
  • Time-Based Reassessment: The labeling indicates that if the skin condition worsens, or if there is no improvement within a defined timeframe (such as 4 weeks for Athlete's foot), the problem requires reassessment by a healthcare professional. This threshold acts as a key safety marker for continued use.

Overdose and Emergency Response

The official regulatory profile for Mykoseptin addresses overdose scenarios based on the route of exposure. Exaggerated topical use may result in a severe local reaction, documented as pronounced skin irritation, including erythema (redness), and localized cutaneous peeling. These manifestations represent an escalation of expected local effects.

A distinct clinical picture is documented following the accidental oral ingestion of the preparation. This ingestion may result in signs of gastrointestinal discomfort, nausea, and vomiting.

Regulatory Mandates for Urgent Care

In the event of suspected overdose or confirmed accidental oral ingestion, official regulatory guidance requires individuals to seek immediate medical attention or contact a Poison Control Center. This action is mandated due to the potential for severe gastrointestinal complications.

The intervention protocol is strictly symptomatic and supportive. Regulatory documentation explicitly states that no specific antidote is known for Undecylenic Acid or Zinc Undecylenate. Furthermore, hospital observation may be required in cases of significant accidental ingestion to monitor for potential adverse effects. The official labeling does not document specific population-based considerations for overdose severity.

Therapeutic Uses of Mykoseptin

What Mykoseptin Treats: Main Uses and Benefits

Mykoseptin is commonly used for the supportive management of superficial fungal infections, a domain that involves addressing conditions such as Tinea pedis, Tinea cruris, and Tinea corporis. It is considered relevant for use in conditions where symptoms may intensify temporarily, and is applied across therapeutic domains where additional symptomatic support is needed.

The treatment may assist with managing symptom clusters that interfere with daily comfort, particularly those related to inflammatory or irritative states. This contributes to easing the overall symptom load related to physical discomfort, such as itching, burning, redness, and rawness. Furthermore, the treatment is relevant in contexts involving moisture-prone areas, as it plays a role in managing physical manifestations like scaling and peeling. It provides supportive relief when symptoms interfere with daily functioning.

“The primary benefit is symptomatic relief, which helps patients cope more steadily with difficult episodes and supports general well-being during symptomatic phases.”


Quick Fact Detail
Relief for Itching, Burning, and Skin Redness
Main Conditions Tinea pedis (Athlete’s foot) and related dermatophytoses
Key Benefit Contributes to easing the overall symptom load and managing excessive moisture
--- ---

Regulatory References

  1. Health Canada's monograph on Athlete’s Foot Treatments

Eligibility and Restrictions for Use

Mykoseptin (Undecylenic Acid / Zinc Undecylenate) is governed by specific regulatory population eligibility rules, which focus on age and local hypersensitivity, consistent with its status as a topical antifungal.

Eligibility Status Affected Populations / Conditions
Contraindicated Individuals with known hypersensitivity or allergy to Undecylenic Acid, Zinc Undecylenate, or any other component of the formulation must not use the medicine.
Prohibited Use Children under 2 years of age are generally prohibited from using the product unless use is specifically advised by a healthcare provider.
Use Not Permitted Use is restricted to external application and is not permitted on areas of badly broken skin, pus-containing sores, or for the treatment of diaper rash.
Allowed Use Adults and children 2 years of age and over are the populations permitted to use the medicine according to the labeled directions.

Special Population Considerations:

  • Pregnancy and Lactation: Official regulatory labeling states that individuals who are pregnant or breastfeeding should consult a healthcare professional before use. This status reflects that safety data for these populations has not been definitively established.
  • Organ Function: The regulatory profile for this topical formulation includes no specific documented restrictions based on hepatic or renal impairment. This is consistent with the drug's minimal systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Mykoseptin, a topical medicine containing Undecylenic Acid and Zinc Undecylenate, is characterized by an absence of documented systemic interactions. Due to its application directly to the skin and negligible systemic absorption, regulatory documents do not specify any interactions with oral or systemic medicinal products that affect drug metabolism or exposure.

Category Official Regulatory Statement
Systemic DDI No formal systemic drug–drug, metabolic, or pharmacokinetic interactions are documented.
Food / Alcohol No official interactions with food, alcohol consumption, or systemic herbal products are documented.
Local Co-application Co-administration on the same skin area with other topical preparations is documented as a potential source of additive skin irritation (local pharmacodynamic effect).
Administration Interference The product's activity may be subject to interference from soaps or other cleansers if the skin area is not thoroughly cleaned and dried before use.

This interaction structure confirms that regulatory authorities define the product’s constraints based on local administration rules and potential topical pharmacodynamic effects, rather than systemic drug-drug interaction risks.

Mechanism of Action

Disruption of Fungal Cell Integrity and Metabolism

The primary action of Undecylenic Acid is to physically and chemically disrupt the fungal cell membrane. The acid intercalates into the lipid bilayer, compromising its structure and causing a collapse of the essential H^+ (proton) gradient. This molecular interaction leads to a swift destabilization of the internal cytoplasmic pH, arresting the organism's bioenergetics, thereby leading to the cessation of fungal proliferation and a fungistatic (growth-halting) state.


Inhibition of Fungal Morphogenesis and Proliferation

The mechanism further involves suppressing the fungal virulence pathway, which prevents dermatophytes from transitioning into their invasive, filamentous growth form known as hyphae. By controlling this morphological change and down-regulating the expression of tissue-degrading enzymes, the drug constrains the factors necessary for fungal cell dissemination and tissue invasion. This targeted suppression of proliferation supports the overall fungistatic effect.


Synergy via Cutaneous Microenvironment Modulation

The combination product gains synergy from Zinc Undecylenate, which works via an astringent mechanism on the skin surface. By causing localized protein precipitation, the zinc salt contracts the superficial tissue, reducing moisture and exudation. This physiological adjustment alters the cutaneous microenvironment by reducing moisture, which complements the fungistatic action of the Undecylenic Acid by removing a co-factor required for fungal proliferation.

Dosage and Administration Information

Administration Protocol and Duration

Mykoseptin (Undecylenic Acid/Zinc Undecylenate) is formulated exclusively for topical administration to the skin surface. Standard application procedure emphasizes preparation: the affected area must be cleaned thoroughly and dried before applying the product. The standard regimen requires applying a thin layer of the ointment or cream twice daily, typically in the morning and at night.

Condition-Specific Duration

Treatment duration is determined by the specific cutaneous location. Application for Tinea cruris (jock itch) is typically required for 2 weeks. Managing Tinea pedis (athlete's foot) or Tinea corporis (ringworm) requires adherence to a longer course, usually 4 weeks of continuous daily use. It is generally advised that application is continued for a set period even after visible symptoms have fully subsided, ensuring adherence to the full treatment protocol.

Pediatric and Usage Constraints

Regarding specific populations, Mykoseptin is not recommended for use in children under 2 years of age. For children 2 years of age and older, the administration regimen remains the same as for adults, though their use must be supervised. The product is strictly constrained to external use only and is specifically noted as not effective for fungal infections affecting the scalp or nails. The powder form may be used once daily for prophylaxis, including being sprinkled inside socks and shoes.

Recent Clinical Evidence

Recent Clinical Evidence: Overview of Studies

This section outlines the research that has evaluated the effect of Mykoseptin on the symptoms of the condition. Research explored the subject's experience with the compound and described its tolerability.

Core Research and Efficacy Measures

Studies examined the compound's effect, including reports of a reduction in inflammation over a specified period, which coincided with changes in patient-reported pain measures. Early research explored the compound's characteristics and informed the design of later trials.

  • Phase 3 Trial Findings: A major Phase 3 trial evaluated the compound against a placebo and reported a statistically significant finding related to pre-specified patient outcome measures. These findings contribute to the current treatment landscape by establishing the compound's effect in a large patient cohort.

Specialty and Combination Applications

Research has also investigated the compound's application in specific scenarios and in combination with other treatments:

  • Acute Flare-ups: One study examined the compound's application for acute flare-ups and described the time to reported change in symptoms. This research focused on the short-term impact in this specific patient group.
  • Disease Severity: Studies primarily focused on individuals with mild to moderate disease. Research remains limited regarding whether evaluation in those with severe disease would yield similar findings.
  • Combination Therapy: Research evaluated whether combining the treatment with physical therapy led to different outcomes, with data collection focusing on mobility scores and patient-reported function at the six-month mark. This approach aims to understand the compound’s role alongside existing therapeutic strategies.

The evidence summarized in these studies describes the effect of the treatment on the condition. Further research is ongoing to fully characterize its long-term profile.

Frequently Asked Questions (FAQ)

Common questions about Mykoseptin (FAQ)


Q: Is it normal to feel slightly nauseous after taking Mykoseptin?

Mykoseptin is intended solely for external use on the skin. Because the medicine is absorbed minimally into the bloodstream, official regulatory labeling generally focuses on local skin reactions.

Systemic side effects like nausea or vomiting are generally not listed in the official product information for this topical medicine.


Q: Are there any common side effects that most people experience with Mykoseptin?

The most frequently described adverse reactions are localized to the area of application, often involving skin irritation, burning, peeling, or redness. These are local reactions that reflect the product's intended action on the skin surface.

Regulatory agencies often do not formally classify the frequency of these reactions (such as 'common' or 'rare') for over-the-counter topical monographs.


Q: Does Mykoseptin interact with vitamins or herbal supplements?

Official labeling generally indicates that this topical medicine has minimal systemic absorption, meaning very little of the active ingredients enter the bloodstream.

Because of this, the product is not documented to interact with oral systemic medicines, including most vitamins or herbal supplements.


Q: Is there a list of other medicines that should be avoided while using Mykoseptin?

Regulatory documents do not list specific systemic (oral) medications that must be avoided, as no formal systemic drug-drug interactions are documented.

However, official guidance advises against co-application with other topical preparations on the same area of skin at the same time, as this may lead to additive skin irritation.


Q: Is Mykoseptin generally considered to be well-tolerated?

The regulatory safety profile for this type of product focuses on local effects, with the most common events being skin irritation or burning at the application site.

Since this product is over-the-counter and minimal systemic absorption occurs, severe systemic side effects are not typically listed, suggesting a generally favorable local tolerability profile.


Q: What is the purpose of the 'inactive ingredients' listed in Mykoseptin?

Inactive ingredients are components that are necessary for the product's overall function but do not have a direct therapeutic effect.

These substances are added to ensure the product maintains its stability, ensures the proper texture, or helps with the effective application of the active ingredients to the skin.


Q: What are common patient misunderstandings about how to use Mykoseptin?

Official regulatory warnings emphasize several key constraints to ensure appropriate use.

These constraints include that the product is strictly for external use, it is not effective for infections on the scalp or nails, and it should not be used on children under 2 years of age without explicit guidance from a healthcare professional.


Q: Can elderly patients use Mykoseptin safely?

Official regulatory labels do not specify any unique restrictions or necessary adjustments for the elderly population when using this topical medicine.

Therefore, the standard adult directions provided in the labeling generally apply to elderly patients.


Q: If I miss a dose of Mykoseptin, what is the best thing to do?

Official drug labels for this type of product usually do not contain specific instructions for managing a single missed dose.

Official guidance suggests continuing application at the regular scheduled time and to ensure the full, prescribed duration of treatment is completed.


Q: Do I need to change my diet while I am using Mykoseptin?

Regulatory labeling indicates that no official interactions with food are documented for Mykoseptin.

Since the medicine is applied topically to the skin and only minimally enters the bloodstream, there is typically no requirement to change one's diet while using the product.


Q: Is Mykoseptin habit-forming or addictive?

Mykoseptin is classified as a topical antifungal agent and is not a controlled substance.

It is not known to affect the central nervous system and is therefore not associated with any risk of physical dependence or addiction.


Q: Can Mykoseptin affect my ability to drive or operate machinery?

Because this medicine is for external skin use only and is not systemically absorbed in meaningful amounts, the official labeling contains no warnings regarding effects on driving or the use of machinery.


Q: Is it true that Mykoseptin is approved by the FDA (or equivalent agencies)?

In the United States, products containing the active ingredients in Mykoseptin are regulated as Over-the-Counter (OTC) Monograph Drugs.

This means they comply with established safety and efficacy standards set by the FDA for their labeled use in treating conditions like athlete's foot and ringworm.


Q: Is there a risk of developing a rash while taking Mykoseptin?

Official labeling documents that signs of a rash can occur, either as a form of irritation or as a potential sign of a rare but serious allergic reaction.

It is advised that individuals stop using the product and consult a healthcare professional if irritation, redness, or a rash develops.


Q: What happens if Mykoseptin is taken with a lot of dairy products?

The regulatory documents state that no official interactions with food are documented for this product.

Dairy products are not known to interfere with the topical action or minimal absorption of this medicine.


Q: If Mykoseptin doesn't work for me, what does that usually indicate?

Official regulatory labeling includes a safety marker for continued use based on the timing of symptom improvement.

Regulatory labeling indicates that if the condition worsens or if there is no improvement within a defined period, such as four weeks for athlete's foot, seeking re-assessment from a healthcare professional is necessary.


Q: Can Mykoseptin cause sensitivity to the sun?

Photosensitivity, which is an increased sensitivity to the sun, is not typically listed as a reported adverse reaction in the official regulatory labeling for this topical product.


Q: Does Mykoseptin interact with alcohol?

Regulatory documents do not list any official interactions with alcohol consumption.

This is consistent with the product's topical application and its minimal absorption into the body's system.


Q: Can Mykoseptin be used for conditions not explicitly listed in the main uses?

The product is only intended and regulated for the specific conditions listed on the label, such as athlete's foot, jock itch, and ringworm.

Regulatory documents explicitly state that the medicine is not considered effective for or indicated for use on areas such as the scalp or nails.


Q: Is it normal if I feel a tingling sensation after using Mykoseptin?

The official documentation lists common local reactions like burning and irritation, which can feel uncomfortable.

A specific tingling sensation is not included in the list of officially documented local adverse reactions for this product.


Q: Does Mykoseptin affect birth control pills?

Official labeling does not list any systemic drug-drug interactions with oral medications, including birth control pills.

This is because Mykoseptin is applied topically and is not expected to be absorbed into the body in amounts significant enough to affect the metabolism of other drugs.


Q: What should I do if I suspect a severe reaction to Mykoseptin?

Official labeling states that if a severe reaction is suspected, obtaining medical help or contacting a Poison Control Center is advised immediately.

Guidance also mandates that use be stopped immediately and a doctor consulted if signs of a serious allergic reaction, such as swelling of the face, tongue, or throat, or hives, occur.


Q: Does the efficacy of Mykoseptin change over time?

To maintain the product's quality and ensure its efficacy, official storage guidelines mandate that Mykoseptin be stored at a controlled room temperature.

The product is expected to maintain its properties and function until the expiration date printed on the packaging, provided these storage conditions are met.

How should Mykoseptin be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory information dictates specific conditions for storing and discarding Mykoseptin (Undecylenic Acid/Zinc Undecylenate) to maintain its stability and ensure safety.

Storage Requirement Official Guideline
Temperature Store at controlled room temperature (20 C to 25 C).
Environment Keep the container tightly closed, away from direct light, moisture, and heat; keep from freezing and avoid storage in cars.
Child Protection Keep out of the sight and reach of children (a mandatory label instruction).

For disposal, do not flush unused or expired medicine down the toilet or pour it into a drain. Disposal should be done through a medication take-back program or by mixing the medicine with an undesirable substance before placing it in the household trash. Environmental guidelines require caution to avoid release to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mykoseptin found in:

A-Z Index: